UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): December 7,
2022
(Exact name of registrant as specified in its charter)
|
Delaware
|
001-38537
|
81-0710585
|
|
(State or other jurisdiction
of incorporation)
|
(Commission
File Number)
|
(I.R.S. Employer
Identification No.)
|
100 Technology Square
Sixth Floor
Cambridge, MA 02139
(Address of principal executive offices, including zip code)
(617) 914-8420
(Registrant’s telephone number, including area code)
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
☐
|
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
|
☐
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class
|
|
Trading
symbol(s)
|
|
Name of each exchange
on which registered
|
|
Common Stock, $0.0001 par value per share
|
|
AVRO
|
|
Nasdaq
Global Select Market
|
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§
230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.
☐
Item 7.01 Regulation
FD Disclosure.
On December 7, 2022, AVROBIO, Inc. (the “Company”) issued a press
release titled “AVROBIO Announces New Positive Clinical Data and
Outlines Clinical Development Plan Following Regulatory Discussions
for its Gaucher Disease Gene Therapy.” A copy of the press release
is furnished as Exhibit 99.1 to this Current Report on Form
8-K.
On December 7, 2022, the Company updated its corporate presentation
for use in meetings with investors, analysts and others. A copy of
the slide presentation is filed as Exhibit 99.2 to this Current
Report on Form 8-K.
The information in Item 7.01 of this Current Report on Form 8-K,
including Exhibits 99.1 and 99.2 attached hereto, shall not be
deemed “filed” for purposes of the Securities Exchange Act of 1934,
as amended (the “Exchange Act”), or otherwise subject to the
liabilities of that section, nor shall it be deemed incorporated by
reference in any filing under the Securities Act of 1933, as
amended, or the Exchange Act, except as expressly set forth by
specific reference in such a filing.
Item 9.01 Financial
Statements and Exhibits.
(d) Exhibits
|
|
AVROBIO, Inc. press release, dated December 7, 2022.
|
|
|
AVROBIO,
Inc. slide presentation, dated December 7, 2022.
|
|
104
|
The
cover page from this Current Report on Form 8-K, formatted in
Inline XBRL.
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned hereunto duly authorized.
|
|
AVROBIO, INC.
|
|
|
|
|
|
Date: December 7, 2022
|
By:
|
|
|
|
|
Geoff MacKay
|
|
|
|
President and Chief Executive Officer
|